Salas-Cervantes MR, Vázquez-Maya L, Hernández-Mendoza L, Palmeros-Morgado G

Language: Spanish
References: 23
Page: 71-76
PDF size: 142.37 Kb.

ABSTRACT

The use of autologus serum in the ophthalmology field has been utilized successfully by several authors, such as a substitute of eye tear in severe dry eye problem or in persistent epithelial defects of the ocular surface. Objective: To observe the effects of autologus serum, such as a coadjuvant treatment, in patients with ocular surface pathology do not respond with traditional treatment. Material and methods: Prospective, longitudinal, not comparative case series study is performed in patients at the external Service of Cornea Department with an epithelial defect of the ocular surface, from March to November 2007. Prior a complete ophthalmologic exploration, from periphery venous blood extraction, in ophthalmology solution, autologous serum is used. Results: 16 eyes (11 patients), 8 females (73%), 3 males (27%), 46 years of age (r = 17-68). The initial tear brake -up time (TBUT) of 2.27 seconds mean, third month mean TBUT of 5.09 seconds. At the beginning the 79.5% of dye staining fluorescein (PDSF) was positive, three months after treatment PDSF result 13.6% positive cases. All the patients refer improvement in symptomatology. Conclusions: Ophthalmology solution of autologus serum, display a great utility in the ocular surface pathology when the conventional treatment is not sufficient.

REFERENCES

1. López- García, Gárcia-Lozano, Martínez-Garchitorena. Use of autologous serum in ophthalmic practice. Arch Soc Esp Ophthalmol 2007; 82: 9-20.

2. Vajpayee RB, Mukerji N, Tandon R, Sharma N, Pandey RM, Biswas NR et al. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol 2003; 87: 1312-1316.

3. Borderie VM, Mourra N, Laroche L. Influence of fetal calf serum, fibroblast growth factors, and hepatocyte growth factor on three-dimensional cultures of human keratocytes in collagen gel matrix. Graefes Arch Clin Exp Ophthalmol 1999; 237: 861-869.

4. Kirschner SE. Persistent corneal ulcers. What to do when ulcers won´t heal. Vet Clin North Am Small Anim Pract 1990; 20: 627-642.

5. Alvarado -Valero MC, Martinez-Toldos JJ, Borras-Blasco J, Alminana-Alminana A, Perez-Ramos JM. Tratamiento de defectos epiteliales persistentes mediante suero autólogo. Arch Soc Esp Oftalmol 2004; 79: 537-542.

6. Kruse FE, Tseng SC. Serum differentially modulates the clonal growth and differentiation of cultured limbal and corneal epithelium. Invest Ophthalmol Vis Sci 1993; 34: 2976-2989.

7. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I et al. Treatment of dry eye by autologous serum application in Sjogren‘s syndrome. Br J Ophthalmol 1999; 83: 390-395.

8. van Setten GB, Tervo T, Tervo K, Tarkkanen A. Epidermal growth factor (EGF) in ocular fluids: presence, origin and therapeutical considerations. Acta Ophthalmol Suppl 1992; 202: 54-59.

9. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing. A multicenter study. Cornea 1992; 11: 311-314.

10. Collins MK, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, Lopez-Rivas A. Growth factors as survival factors: Regulation of apoptosis. Bioessays 1994; 16: 133-138.

11. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110: 113-121.

12. Ohashi Y, Motokura M, Kinoshita Y, Mano T, Watanabe H, Kinoshita S et al. Presence of epidermal growth factor in human tears. Invest Ophthalmol Vis Sci 1989; 30: 1879-1882.

13. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 1996; 15: 605-614.

14. Fredj-Reygrobellet D, Plouet J, Delayre T, Baudouin C, Bourret F, Lapalus P. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr Eye Res 1987; 6: 1205-1209.

15. Yoshino K, Garg R, Monroy D, Ji Z, Pflugfelder SC. Production and secretion of transforming growth factor beta (TGF-beta) by the human lacrimal gland. Curr Eye Res 1996; 15: 615-624.

16. Wilson SE, Lloyd SA, Kennedy RH. Basic fibroblast growth factor (FGFb) and epidermal growth factor (EGF) receptor messenger RNA production in human lacrimal gland. Invest Ophthalmol Vis Sci 1991; 32: 2816-2820.

17. Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi A, Shimazaki J et al. Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 2003; 87: 1279-1283.

18. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85: 1188-1197.

19. Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol 1983; 101: 1046-1048.

20. Phan TM, Foster CS, Shaw CD, Zagachin LM, Colvin RB. Topical fibronectin in an alkali burn model of corneal ulceration in rabbits. Arch Ophthalmol 1991; 109: 414-419.

21. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996; 169: 159-166.

22. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999; 106: 1984-1989.

23. Díaz-Valle D, Benítez del Castillo SJM, Díaz RE, Toledano FM, Arteaga SA, Sayagués GO. Manejo de la queratopatía neurotrófica mediante tarsorrafia con cianoacrilato y suero autólogo. Arch Soc Esp Oftalmol 2003; 78: 119-122.